Mind Medicine (MindMed) Inc. (NASDAQ: MNMD) has announced the appointment of Brandi L. Roberts, a CPA with over 25 years of financial leadership experience within the life sciences industry, as its Chief Financial Officer (CFO). Roberts is set to join the company's executive leadership team effective June 2, 2025.
Roberts has a proven track record, having served as CFO and Executive Vice President of Longboard Pharmaceuticals, where she helped lead the company through its IPO, multiple financings, and ultimately, its $2.6 billion acquisition by Lundbeck in 2024.
In connection with her appointment, MindMed will grant Roberts an option to purchase 500,000 common shares of the company and 125,000 performance share units, subject to certain performance metrics, as inducement awards. The option will have an exercise price equal to the closing price of MindMed’s common shares on May 30, 2025, and will vest over a four-year period, subject to her continued employment. The performance share units will vest on the third anniversary of the grant date, subject to continued service through the vesting date.
MindMed's CEO, Rob Barrow, expressed his confidence in Roberts, emphasizing her financial acumen, strategic vision, and deep biotech sector expertise. Roberts also shared her excitement in joining MindMed, acknowledging the company's potential breakthrough with its lead product candidate MM120 orally disintegrating tablet for generalized anxiety disorder (GAD) and major depressive disorder (MDD).
MindMed is a late-stage clinical biopharmaceutical company focused on developing novel product candidates to treat brain health disorders. The company's mission is to be the global leader in the development and delivery of treatments that unlock new opportunities to improve patient outcomes. MindMed trades on NASDAQ under the symbol MNMD. The market has reacted to these announcements by moving the company's shares -2.06% to a price of $7.15. For more information, read the company's full 8-K submission here.
